LeMaitre Vascular, Inc. $LMAT Stock Position Boosted by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC lifted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.6% during the 1st quarter, HoldingsChannel.com reports. The fund owned 1,476,813 shares of the medical instruments supplier’s stock after buying an additional 51,825 shares during the period. LeMaitre Vascular makes up about 3.2% of Conestoga Capital Advisors LLC’s portfolio, making the stock its 7th biggest holding. Conestoga Capital Advisors LLC owned about 0.06% of LeMaitre Vascular worth $161,224,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Illinois Municipal Retirement Fund lifted its holdings in LeMaitre Vascular by 1.1% in the fourth quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock worth $906,000 after acquiring an additional 123 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in shares of LeMaitre Vascular by 4.6% in the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock worth $256,000 after purchasing an additional 139 shares during the last quarter. State of Alaska Department of Revenue boosted its position in LeMaitre Vascular by 1.2% during the 4th quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock valued at $971,000 after purchasing an additional 147 shares during the period. Federated Hermes Inc. grew its stake in LeMaitre Vascular by 0.4% during the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock worth $3,294,000 after buying an additional 155 shares during the last quarter. Finally, Pictet Asset Management Holding SA grew its stake in LeMaitre Vascular by 5.5% during the 1st quarter. Pictet Asset Management Holding SA now owns 3,259 shares of the medical instruments supplier’s stock worth $356,000 after buying an additional 169 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,928 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $107.00, for a total value of $313,296.00. Following the completion of the transaction, the insider directly owned 3,749 shares in the company, valued at $401,143. This trade represents a 43.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bridget A. Ross sold 5,044 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the transaction, the director owned 3,942 shares in the company, valued at $437,956.20. This represents a 56.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 54,453 shares of company stock valued at $5,906,174. Company insiders own 7.40% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on LMAT shares. Barrington Research reiterated an “outperform” rating and issued a $120.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, June 3rd. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday. Wells Fargo & Company increased their price objective on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Citizens Jmp lifted their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $112.60.

LeMaitre Vascular Trading Up 2.9%

Shares of LMAT stock opened at $98.74 on Thursday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. LeMaitre Vascular, Inc. has a 1 year low of $79.00 and a 1 year high of $118.01. The stock has a fifty day moving average of $99.17 and a two-hundred day moving average of $97.02. The firm has a market capitalization of $2.26 billion, a PE ratio of 36.44, a price-to-earnings-growth ratio of 2.67 and a beta of 0.52.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. The company had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The company’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period last year, the company earned $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 3 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st were paid a dividend of $0.25 per share. The ex-dividend date of this dividend was Thursday, May 21st. This represents a $1.00 annualized dividend and a yield of 1.0%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 36.90%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.